Journal of International Psychiatry

【Abstract】Objective: To explore the effect of paroxetine in patients with perimenopausal depression and the mechanism of its effect on serum neurotransmitter and sex hormone levels. Methods: From July 2019 to July 2021, 89 patients with perimenopausal depressive disorder were used as the research object. The control group was given estrogen replacement therapy combined with psychotherapy for 44 patients, and the observation group was treated with paroxetine for 45 patients, and the two groups were compared. Depressive conditions, serum sex hormone levels, neurotransmitter levels, adverse reactions. Results: After 12 months of treatment, the level of estradiol in the observation group was higher than that in the control group (P<0.05), and the levels of luteinizing hormone and follicle-stimulating hormone were lower than those in the control group (P<0.05); the observation groups Kupperman score and The scores of Hamilton Depression Scale were lower than those of the control group (P<0.05); the brain-derived neurotrophic factor, serotonin and norepinephrine levels in the observation group were higher than those in the control group (P<0.05); There was no statistically significant difference in the number of drowsiness, gastrointestinal adverse reactions, and headaches compared with the control group (P>0.05). Conclusion: Paroxetine is effective in treating patients with perimenopausal depressive disorder. It can significantly increase the level of neurotransmitters, regulate the level of serum sex hormones, and improve the depressive state of patients.

[Keywords] Paroxetine; perimenopausal depression; sex hormones; neurotransmitters